Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

House Health Subcommittee Leaders Preview Life Sciences Priorities

Washington, DC, March 22, 2013 — Elise Viebeck reports in The Hill that the leaders of the House Energy and Commerce Committee’s Health Subcommittee have vowed to bring fresh life sciences debates to the fore in the current Congress. 

Reps. Joe Pitts (R-PA) and Michael Burgess (R-TX), the respective chairman and vice-chairman of the Health Subcommittee, said they intended to be “more pro-active with our messaging,” particularly on issues concerning the FDA. 

“Although the FDA is under the administrative branch, we are responsible for the product that they produce,” Burgess said in a conversation with reporters.  “We darn sure better have the oversight of what they’re doing, and why they’re doing it.”

Specifically, Pitts and Burgess said they want to look at incentives for biologics, the integrity of the drug supply chain and the FDA’s broader attitude toward innovation.

The subcommittee has legislative jurisdiction over, among other things, biomedical research and development; health information technology; private and public health insurance (Medicare, Medicaid); the regulation of food, drugs, and cosmetics; the Department of Health and Human Services; and the National Institutes of Health.

To read Viebeck’s full article in The Hill, click here.